Verastem partner reports 41% ORR for VS-7375 in heavily pre-treated KRAS G12D PDAC at ESMO 2025

Verastem, Inc.

ORR of 41% (24/59) in heavily pre-treated advanced KRAS G12D PDAC at 600 mg daily; DCR 96.7%.
Month-four OS rate 92.2%, median OS not reached; median PFS 5.52 months, 4-month PFS rate 78.2%.
91.5% of patients had tumor reduction; 47% still on treatment; longest treatment >1 year.
Safety: 30.3% Grade 3 TRAEs, 3% discontinuation due to TRAEs, no TRAE-related deaths; mean dose intensity 93%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.